Evidence mapPaperPMID 31253191Full record

ArticleAlzheimer's research & therapy2019

Spermidine/spermine-N

Leslie A Sandusky-Beltran, Andrii Kovalenko, Chao Ma, John Ivan T Calahatian, Devon S Placides, Mallory D Watler, Jerry B Hunt, April L Darling, Jeremy D Baker, Laura J Blair and 10 more

Open access · goldAbstract read
In one paragraph

Article in Alzheimer's research & therapy, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.

0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed
2.0field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

32 citing papers in PubMed, 50 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Article
  4. Article
  5. Spermidine in Alzheimer's Disease: Evidence from Animal Models and Human Studies.Degenerative neurological and neuromuscular disease · 2026
    Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Review
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 2 institutions in 1 country.

Leslie A Sandusky-BeltranByrd Alzheimer's Institute, Department of Pharmaceutical Sciences, University of South Florida, 4001 E. Fletcher Ave, Tampa, FL, 33613, USA.
Andrii KovalenkoByrd Alzheimer's Institute, Department of Pharmaceutical Sciences, University of South Florida, 4001 E. Fletcher Ave, Tampa, FL, 33613, USA.
Chao MaByrd Alzheimer's Institute, Department of Molecular Pharmacology and Physiology, University of South Florida, Tampa, FL, 33613, USA.
John Ivan T CalahatianByrd Alzheimer's Institute, Department of Pharmaceutical Sciences, University of South Florida, 4001 E. Fletcher Ave, Tampa, FL, 33613, USA.
Devon S PlacidesByrd Alzheimer's Institute, Department of Pharmaceutical Sciences, University of South Florida, 4001 E. Fletcher Ave, Tampa, FL, 33613, USA.
Mallory D WatlerByrd Alzheimer's Institute, Department of Pharmaceutical Sciences, University of South Florida, 4001 E. Fletcher Ave, Tampa, FL, 33613, USA.
Jerry B HuntByrd Alzheimer's Institute, Department of Pharmaceutical Sciences, University of South Florida, 4001 E. Fletcher Ave, Tampa, FL, 33613, USA.
April L DarlingByrd Alzheimer's Institute, Department of Molecular Medicine, University of South Florida, Tampa, FL, 33613, USA.
Jeremy D BakerByrd Alzheimer's Institute, Department of Molecular Medicine, University of South Florida, Tampa, FL, 33613, USA.
Laura J BlairByrd Alzheimer's Institute, Department of Molecular Medicine, University of South Florida, Tampa, FL, 33613, USA.
Mackenzie D MartinByrd Alzheimer's Institute, Department of Molecular Medicine, University of South Florida, Tampa, FL, 33613, USA.
Sarah N FontaineByrd Alzheimer's Institute, Department of Molecular Medicine, University of South Florida, Tampa, FL, 33613, USA.
Chad A DickeyByrd Alzheimer's Institute, Department of Molecular Medicine, University of South Florida, Tampa, FL, 33613, USA.
April L LussierByrd Alzheimer's Institute, Department of Molecular Pharmacology and Physiology, University of South Florida, Tampa, FL, 33613, USA.
Edwin J WeeberByrd Alzheimer's Institute, Department of Molecular Pharmacology and Physiology, University of South Florida, Tampa, FL, 33613, USA.
Maj-Linda B SelenicaByrd Alzheimer's Institute, Department of Pharmaceutical Sciences, University of South Florida, 4001 E. Fletcher Ave, Tampa, FL, 33613, USA.
Kevin R NashByrd Alzheimer's Institute, Department of Molecular Pharmacology and Physiology, University of South Florida, Tampa, FL, 33613, USA.
Marcia N GordonByrd Alzheimer's Institute, Department of Molecular Pharmacology and Physiology, University of South Florida, Tampa, FL, 33613, USA.
Dave MorganByrd Alzheimer's Institute, Department of Molecular Pharmacology and Physiology, University of South Florida, Tampa, FL, 33613, USA.
Daniel C LeeByrd Alzheimer's Institute, Department of Pharmaceutical Sciences, University of South Florida, 4001 E. Fletcher Ave, Tampa, FL, 33613, USA. dlee1@health.usf.edu.ORCID 0000-0002-9718-5579
University of South Florida · USNeurosciences Institute · US

Funding

Emerging Roles of Higher-order Polyamines During TauopathiesR01AG054559 · NIA · UNIVERSITY OF SOUTH FLORIDA · PI LEE, DANIEL CARL · 2017 to 2021
$2.4M
NIA NIH HHS R01 AG054559
6 · The paper itself

Abstract

backgroundTau stabilizes microtubules; however, in Alzheimer's disease (AD) and tauopathies, tau becomes hyperphosphorylated, aggregates, and results in neuronal death. Our group recently uncovered a unique interaction between polyamine metabolism and tau fate. Polyamines exert an array of physiological effects that support neuronal function and cognitive processing. Specific stimuli can elicit a polyamine stress response (PSR), resulting in altered central polyamine homeostasis. Evidence suggests that elevations in polyamines following a short-term stressor are beneficial; however, persistent stress and subsequent PSR activation may lead to maladaptive polyamine dysregulation, which is observed in AD, and may contribute to neuropathology and disease progression.

methodsMale and female mice harboring tau P301L mutation (rTg4510) were examined for a tau-induced central polyamine stress response (tau-PSR). The direct effect of tau-PSR byproducts on tau fibrillization and oligomerization were measured using a thioflavin T assay and a N2a split superfolder GFP-Tau (N2a-ssGT) cell line, respectively. To therapeutically target the tau-PSR, we bilaterally injected caspase 3-cleaved tau truncated at aspartate 421 (AAV9 Tau ΔD421) into the hippocampus and cortex of spermidine/spermine-N

resultsTau induced a unique tau-PSR signature in rTg4510 mice, notably in the accumulation of acetylated spermidine. In vitro, higher-order polyamines prevented tau fibrillization but acetylated spermidine failed to mimic this effect and even promoted fibrillization and oligomerization. AAV9 Tau ΔD421 also elicited a unique tau-PSR in vivo, and targeted disruption of SSAT prevented the accumulation of acetylated polyamines and impacted several tau phospho-epitopes. Interestingly, SSAT knockout mice presented with altered behavior in the rotarod task, the elevated plus maze, and marble burying task, thus highlighting the impact of polyamine homeostasis within the brain.

conclusionThese data represent a novel paradigm linking tau pathology and polyamine dysfunction and that targeting specific arms within the polyamine pathway may serve as new targets to mitigate certain components of the tau phenotype.

Indexed as

Stress, PhysiologicalAcetyltransferasesAnimalsDiamine N-AcetyltransferaseFemaleHippocampusMaleMice, Inbred C57BLMice, KnockoutPolyaminesProtein Aggregation, PathologicalTauopathiestau ProteinsAcetyltransferasesDiamine N-AcetyltransferaseMapt protein, mousePolyaminestau ProteinsAlzheimer’s diseaseHippocampusPolyamine dysregulationTau

Identifiers

PMID31253191
PMCPMC6599347
OpenAlexW2955966925

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.